Status:
UNKNOWN
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19
Lead Sponsor:
Assiut University
Conditions:
COVID-19 Pneumonia
Eligibility:
All Genders
18-90 years
Brief Summary
1. To determine the risk of COVID -19 in patients who use ACEI and ARBS 2. To determine the Effect of ACEI and ARBS on COVID -19 infection . 3. To determine the Severity of COVID -19 in patients who u...
Detailed Description
SARS -CORONA VIRUS -2 (COVID-19 disease) is an infectious disease caused by the SARS-CoV-2 virus The virus enters the body through the nose, eyes, or mouth. The spike protein binds specifically to the...
Eligibility Criteria
Inclusion
- Age \>18 years old.
- patients who use ACEI
- patients who use ARBs
- patients who use other antihypertensive drugs(for example ca channel blockers or Beta blockers)
- Non hypertensive persons with matched age and sex
Exclusion
- \< 18 years old.
- Pregnant or breast-feeding patients.
- Patients with autoimmune disease.
- Patients with multi organ failure, active cancer, renal insufficiency or chronic kidney disease.
- Patients received immunosuppressive drugs.
- Immune compromised patients.
- Patients with obstructive lung disease
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05398731
Start Date
June 1 2022
End Date
May 1 2023
Last Update
June 7 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.